Wellyz Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-06-2024
- Paid Up Capital ₹ 0.60 M
as on 21-06-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 126.17%
(FY 2022)
- Profit 63.98%
(FY 2022)
- Ebitda -7858.53%
(FY 2022)
- Net Worth -4.25%
(FY 2022)
- Total Assets 46.63%
(FY 2022)
About Wellyz Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M, as per Ministry of Corporate Affairs (MCA) records.
Debasree Dutta, Mamta Kumari, Archana Byahut, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51909WB2019PTC232439
- Company No.
232439
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Bardhaman, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Wellyz Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sumedha Mukherjee  | Managing Director | 13-Jun-2019 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mamta Kumari | Director | 24-Feb-2020 | Current |
| Debasree Dutta | Director | 24-Feb-2020 | Current |
| Archana Byahut | Director | 13-Jun-2019 | Current |
| Priyanka Garai | Director | 24-Feb-2020 | Current |
| Koyel Paul | Director | 13-Jun-2019 | Current |
Financial Performance of Wellyz Pharmaceutical.
Wellyz Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 126.17% increase. The company also saw a substantial improvement in profitability, with a 63.98% increase in profit. The company's net worth dipped by a decrease of 4.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wellyz Pharmaceutical?
In 2020, Wellyz Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wellyz Pharmaceutical?
Wellyz Pharmaceutical has a workforce of 18 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wellyz Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wellyz Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
